Deals Of The Week: Mylan/Biocon, Merck/Lycera, Lilly/Qiagen
Executive Summary
A pending regulatory decision in the U.S. and Europe for oncology drug RA 223 and improving sales of AMD drug Eylea, both brought in through partnership activity, may bring some calm to the recently stormy seas traveled by Bayer Healthcare.